SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.
NCT06614322
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy. The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC). This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Painful Peripheral Neuropathy
- Diabetic Peripheral Neuropathic Pain (DPN)
- Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Idiopathic Peripheral Neuropathy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Rochester
- Last updated on ClinicalTrials.gov
- September 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Beth Israel Deaconess Medical Center for Autonomic and Peripheral Nerve Disorders · Boston, MA
New York · 2
- Ichan School of Medicine at Mount Sinai · New York, NY
- University of Rochester · Rochester, NY
Pennsylvania · 1
- University of Pittsburgh · Pittsburgh, PA
Utah · 1
- University of Utah · Salt Lake City, UT
Vermont · 1
- University of Vermont · Burlington, VT
Virginia · 1
- VCU Medical Center · Richmond, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.